- Home
- OTLK
as 02-04-2025 4:00pm EST
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | ISELIN |
| Market Cap: | 64.6M | IPO Year: | 2016 |
| Target Price: | $21.00 | AVG Volume (30 days): | 892.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.06 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.87 - $12.85 | Next Earning Date: | 02-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 396.84% |
Latest Outlook Therapeutics Inc. News
OTLK Breaking Stock News: Dive into OTLK Ticker-Specific Updates for Smart Investing
GlobeNewswire
21 hours ago
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment
GlobeNewswire
5 days ago
Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors
GlobeNewswire
13 days ago
Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD
GlobeNewswire
14 days ago
Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
MT Newswires
20 days ago
Sector Update: Health Care Stocks Rise Late Afternoon
MT Newswires
20 days ago
Outlook Therapeutics Shares Fall After Reporting Trial Results for ONS-5010 in Wet AMD
Benzinga
20 days ago
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
GlobeNewswire
20 days ago
Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial
Compare OTLK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OTLK Outlook Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.